Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression.
Lloyd, A, Hickie, I, Hickie, C et al. · Clinical and experimental immunology · 1992 · DOI
Quick Summary
This study compared immune system function in patients with ME/CFS, people with depression, and healthy individuals. Researchers found that ME/CFS patients had weaker immune responses than both groups, suggesting their immune problems are distinct from depression-related immune changes. This indicates that ME/CFS involves direct immune system dysfunction rather than these problems simply being caused by depression.
Why It Matters
This study helped establish that ME/CFS involves genuine immune dysfunction independent of depression, validating biological disease mechanisms rather than attributing symptoms solely to psychiatric causes. Understanding that immune abnormalities are intrinsic to ME/CFS rather than secondary to depression supports the search for biological treatments and changes perceptions of disease legitimacy.
Observed Findings
CFS patients showed impaired lymphocyte proliferation responses to PHA stimulation compared to both depression patients and healthy controls
CFS patients demonstrated reduced or absent delayed-type hypersensitivity (DTH) skin responses versus both comparison groups
The prevalence and magnitude of cell-mediated immune abnormalities differed between CFS and major depression groups
Immune abnormalities in CFS were not attributable to comorbid depression alone
Inferred Conclusions
Cell-mediated immunity disturbances in CFS have a direct biological relationship to disease etiology rather than being secondary to depression
Immune dysfunction in CFS represents a distinct immunopathological pattern different from depression-associated immune changes
Depression commonly present in CFS patients does not explain the observed immune abnormalities
Remaining Questions
What specific immune mechanisms (cytokine dysregulation, specific T-cell subset abnormalities, etc.) drive the observed lymphocyte and DTH response impairments?
Do these immune abnormalities precede symptom onset or develop secondary to illness, and do they correlate with symptom severity or type?
What is the functional significance of reduced DTH responses and impaired PHA proliferation for actual infection control and clinical outcomes in ME/CFS?
What This Study Does Not Prove
This study does not prove that immune dysfunction causes ME/CFS symptoms—only that it is associated with the condition. It does not identify which specific immune mechanisms drive illness or explain why these abnormalities develop. The cross-sectional design cannot establish temporal relationships or determine whether immune changes precede or follow symptom onset.
Are immune abnormalities stable over time, do they change with disease progression or treatment, and can they serve as biomarkers for diagnosis or prognosis?